Predictive Factors for the Common Adverse Maternal and Fetal Outcomes in Pregnancies Complicated by Systemic Lupus Erythematosus

• Published in: Women's health reports (New Rochelle, N.Y.) Vol. 5; no. 1; pp. 434 - 443
• Main Authors: Dai, Qianwen, Li, Mengtao, Tian, Xinping, Song, Yijun, Zhao, Jiuliang
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc., publishers 01.05.2024; Mary Ann Liebert
• Subjects: adverse pregnancy outcomes; Original Article; predictors; preeclampsia; pregnancy; preterm birth; systemic lupus erythematosus; preterm birth; predictors; systemic lupus erythematosus; preeclampsia; adverse pregnancy outcomes; pregnancy
• ISSN: 2688-4844; 2688-4844
• DOI: 10.1089/whr.2023.0180

Objectives: This study aimed to evaluate the outcomes of pregnancy in patients with systemic lupus erythematosus (SLE). It focused on identifying clinical and laboratory markers that could predict the common adverse pregnancy outcomes (APOs) after 20 weeks of gestation, namely preeclampsia (PE) and preterm birth (PTB) in them. Methods: Pregnant SLE women who delivered at the study center from 2010 to 2023 were retrospectively analyzed. Categorical variables were evaluated using the chi-square test or Fisher’s exact test, while continuous variables underwent Mann–Whitney U testing. Stepwise regression was used to assess the predictors of pregnancy outcomes. Results: The study enrolled 445 pregnancies in 408 women diagnosed with SLE. Of these, 202 pregnancies (45.4%) resulted in at least one APO. Disease flare-ups, hypertension, and proteinuria during the first trimester were primary predictors of at least one APO and PTB. The most frequently recorded maternal adverse outcome was PE (14.6%), while PTB accounted for 32.6% of fetal adverse outcomes. Multivariate regression analysis identified hypertension, history of PE, associated antiphospholipid syndrome (APS), proteinuria, and low serum C4 in the first trimester as independent risk factors for PE. Regular follow-ups at our center correlated with lower risks of APOs, PE, and PTB. APS also emerged as a risk factor for PTB, whereas the use of hydroxychloroquine (HCQ) during pregnancy seemed to protect against PTB. Conclusion: For pregnancies complicated by SLE, we recommend early pregnancy screening for proteinuria—even in the absence of lupus nephritis—as well as continued use of HCQ and routine prenatal care throughout pregnancy.